AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

Overview of attention for article published in BMC Cancer, July 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 1 news outlet
twitter: 2 X users

patent: 1 patent

Citations

dimensions_citation: 56 Dimensions

Readers on

mendeley: 71 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

METHODS AND COMPOSITIONS FOR TREATING CANCER

Application WO-2023279092-A3

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.